Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Evaluation of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT01118052 is registered in ClinicalTrials.gov with Gynecologic Oncology Group as lead sponsor.

NCT NCT01118052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01118052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Evaluation of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Lead sponsor
Gynecologic Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
November 1, 2010
Completion date
July 16, 2016
Enrollment
22 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube carcinoma, primary peritoneal carcinoma, recurrent ovarian carcinoma